Chondrosarcoma is the second most common sarcoma in bone malignancy and is characterized by a high metastatic potential. Angiogenesis is essential for the cancer metastasis. Endothelin-1 (ET-1) has been implicated in tumor angiogenesis and metastasis. However, the relationship of ET-1 with vascular endothelial growth factor (VEGF) expression and angiogenesis in human chondrosarcoma cells is mostly unknown. Here, we found that the expression of ET-1 and VEGF were correlated with tumor stage and were significantly higher than that in the normal cartilage. Exogenous ET-1 with chondrosarcoma cells promoted VEGF expression and subsequently increased migration and tube formation in endothelial progenitor cells. ET-1 increased VEGF expression and angiogenesis through ET A R, integrin-linked kinase (ILK), Akt and hypoxia-inducible factor-1a (HIF-1a) signaling cascades. Knockdown of ET-1 decreased VEGF expression and also abolished chondrosarcoma conditional medium-mediated angiogenesis in vitro as well as angiogenesis effects in the chick chorioallantoic membrane and Matrigel plug nude mice model in vivo. In addition, in the xenograft tumor angiogenesis model, knockdown of ET-1 significantly reduced tumor growth and tumor-associated angiogenesis. Taken together, these results indicate that ET-1 occurs through ET A R, ILK and Akt, which in turn activates HIF-1a, resulting in the activation of VEGF expression and contributing to the angiogenesis and tumor growth of human chondrosarcoma cells.
INTRODUCTION
Chondrosarcoma is the second most common sarcoma arising in bone malignancy after myeloma and osteosarcoma. It is characterized by its rapid-progressing, pathologically diverse and highly malignant form. 1 Currently, surgical resection remains the primary mode of remedy for chondrosarcoma treatment. The distant metastatic potential of chondrosarcoma also has been reported previously. 1 Therefore, better strategies of treatment will ultimately require understanding of the molecular mechanisms of the metastasis step of human chondrosarcoma and identifying and specifically targeting the critical signaling effectors.
Tumor growth and metastasis depend on the ability of cells to induce their own blood supply. Angiogenesis is essential for the development, growth and progression of human cancers. 2, 3 The angiogenic process is balanced by various positive (such as vascular endothelial growth factor (VEGF)) and negative (such as thrombospondin-1) regulatory molecules of endothelial proliferation and migration. 4 VEGF-A has been shown to play an important role in wound healing, embryonic development, growth of certain solid tumors and angiogenesis. 5 Treatment with a VEGF antagonist significantly attenuated angiogenesis and tumor growth. 4 Therefore, VEGF is a critical target for cancer therapy and metastasis.
Endothelin-1 (ET-1) is a potent vasoconstrictor and the most abundantly and widely expressed member of the endothelin family of proteins (ET-1, ET-2 and ET-3). Aberrant ET-1 is implicated in the pathobiology of a wide range of human tumors. 6 ET-1 acts as an autocrine or paracrine growth, survival and angiogenic factor selectively through the specific receptor ET A R 7 or ET B R 8 in several tumor cell types. Although ET-1 is associated with many secreted factors and matrix proteins, it plays an important role in tumor progression and angiogenesis. 9 However, a newly identified mechanism of tumor growth and angiogenesis has been observed, which associates with VEGF secreted in tumor cells, such as melanoma, 10 meningiomas, 11 and prostate cancer. 12 Therefore, ET-1-induced, VEGF-dependent angiogenesis may be a novel target for tumor angiogenesis and metastasis.
ET-1 has been demonstrated to induce migration in human chondrosarcoma through matrix metalloproteinase-13 upregulation. 13 On the other hand, VEGF is a potent angiogenic factor that is pivotal in angiogenesis and tumor growth. Although a role for ET-1 in VEGF production has been implicated in some cancer cells, the signaling pathway for ET-1 in VEGF expression in human chondrosarcoma has not been studied extensively. In this study, we explored the intracellular signaling pathways involved in ET-1-induced VEGF production in human chondrosarcoma. The results show that ET-1 and ET A R interaction activates integrin-linked kinase (ILK), Akt and the hypoxia-inducible factor-1a (HIF-1a) pathway, leading to the upregulation of VEGF expression, resulting in angiogenesis and tumor growth.
RESULTS

ET-1 induces VEGF expression and promotes angiogenesis in vitro
ET-1 has been reported to promote VEGF-dependent angiogenesis in human cancer cells. 14, 15 However, little is known about the correlation between ET-1 and VEGF in human chondrosarcoma cells. We first examined tissues obtained from human chondrosarcoma patients for the expression of the ET-1 and VEGF using immunohistochemistry (IHC). The expression of ET-1 and VEGF in chondrosarcoma patients was significantly higher than that in the normal cartilage (Figures 1a and b) . In addition, the high level of ET-1 expression correlated strongly with VEGF expression and tumor stage (Figures 1a and b) . The quantitative data also show that the expression of ET-1 is correlated with the expression of VEGF in human chondrosarcoma patients ( Figure 1c) . Next, we directly applied ET-1 to human chondrosarcoma cell line and examined the expression of VEGF (an important angiogentic factor). The results showed that ET-1 increased VEGF mRNA expression in a concentration-dependent manner (Figure 2a ). On the other hand, stimulation of cells with ET-1 also led to increase in the protein expression of VEGF in a concentration-dependent manner, as shown by enzyme-linked immunosorbent assay (ELISA) and western blotting (Figures 2b  and c) . In angiogenic processes, endothelial cells must undergo migration, proliferation and tube formation to form new blood vessels. 16 We then examined whether ET-1-dependent VEGF expression induced angiogenesis by using an endothelial progenitor cell (EPC) model in vitro. We found that the conditioned medium (CM) from ET-1-treated chondrosarcoma cells promoted migration and tube formation in EPCs concentration-dependently (VEGF was used as positive control) (Figures 2d and e) . To elucidate whether ET-1-dependent VEGF plays an important role in angiogenesis, the VEGF antibody was used. As shown in Figures 2d and e, pre-treatment of JJ012 cells with VEGF antibody reduced ET-1-induced migration and tube formation in EPCs. These data indicated that ET-1-dependent VEGF expression promotes angiogenesis in human chondrosarcoma cells.
The ET A R/ILK/Akt signaling pathway is involved in ET-1-mediated VEGF expression and angiogenesis The exertion of ET-1 affects VEGF and angiogenesis by binding to the cell surface of two distinct receptors (ET A R and ET B R). 17, 18 Therefore, we hypothesized that the ET receptors may be involved in ET-1-induced VEGF expression and angiogenesis in human chondrosarcoma cells. Pre-treatment of chondrosarcoma cells with ET A R antagonist BQ123 but not ET B R antagonist BQ788 abolished ET-1-increased VEGF expression (Figures 3a and b) . On the other hand, CM from chondrosarcoma also demonstrated that BQ123 but not BQ788 reduced ET-1-mediated migration and tube formation in EPCs. These data suggest that ET-1-dependent VEGF promoted angiogenesis through ET A R.
The ILK/Akt signaling pathway has been reported to regulate VEGF expression and angiogenesis. 19 We next examined whether the ILK/Akt pathway is involved in the ET-1-mediated VEGF expression and angiogenesis. Pre-treatment of JJ012 cells with ILK inhibitor KP392 or Akt inhibitor (1L-6-hydroxymethylchiro-inositol-2-((R)-2-O-methyl-3-O-octadecylcarbonate)) reduced ET-1-induced expression of VEGF (Figures 4a and b) . In addition, ET-1-mediated EPC migration and tube formation was also diminished by pre-treatment with ILK inhibitor KP392 or Akt inhibitor. Moreover, incubation of JJ012 cells with ET-1 increased ILK kinase activity and Akt phosphorylation in a time-dependent manner ( Figure 4e ). On the basis of these results, it appears that the ET-1 acted through the ILK/Akt pathway to enhance VEGF expression and angiogenesis in human chondrosarcoma cells.
Involvement of HIF-1a in ET-1 induced angiogenesis and VEGF expression Recent studies have documented that ET-1 promoted VEGF expression by HIF-1a transactivation. 20, 21 Pre-treatment of JJ012 cells with HIF-1a inhibitor antagonized ET-1-increased VEGF expression (Figures 5a and b) . On the other hand, HIF-1a inhibitor treatment also reduced ET-1-mediated EPC migration and tube formation. To confirm the results from the chemical inhibitor, Figures S1B-D) . It has been reported that HIF-1a nuclear translocation is necessary for the transcriptional activation of HIF-1-regulated VEGF expression. 22 We therefore used western blotting to examine the nuclear translocation of HIF-1a protein after ET-1 treatment. We found that ET-1 increased the accumulation of HIF-1a in the nucleus in a time-dependent manner ( Figure 5e ). We also further examined whether ET-1 could upregulate HIF-1 activation through the increase of mRNA level. Stimulation of JJ012 cells with ET-1 induced HIF-1a mRNA expression (Figure 5f ). Therefore, HIF-1a transactivation plays a critical role in ET-1-induced VEGF expression and angiogenesis.
We next explored whether the ET A R/ILK/Akt pathway is an upstream molecule in ET-1-mediated HIF-1a transactivation. Our data found that ET A R, ILK or Akt inhibitor but not ET B R inhibitor reduced ET-1-increased mRNA expression of HIF-1a (Figures 6a  and b) . Furthermore, the in vivo binding of HIF-1a to the HRE element of the VEGF promoter occurred after ET-1 stimulation (Figure 6c ). The binding of HIF-1a to the HRE element by ET-1 was attenuated by KP392 and Akt inhibitor (Figure 6c ). HIF-1a activation was also evaluated by analyzing the HRE luciferase activity. As shown in Figure 6d (Figures 7f and g ). Overall, these results indicated that ET-1 from chondrosarcoma promotes angiogenesis in vivo.
To further investigate whether knockdown of ET-1 is able to inhibit tumor-induced angiogenesis, a xenograft tumor-induced angiogenesis model was used. Chondrosarcoma cells were mixed with Matrigel and injected into the flanks of mice. We found that JJ012/control-shRNA cells profoundly induced tumor mass formation. However, knockdown of ET-1 reduced tumor growth in mice (Figures 8a-c) . On the other hand, we also quantified the level of angiogenesis by determining the hemoglobin content of the plugs and found that reducing ET-1 expression diminished chondrosarcoma-induced angiogenesis in vivo (Figure 8d ). The hemoglobin content also correlated with tumor volume on these tumors (Figure 8e ). Overall these results suggest that ET-1 promotes angiogenesis and tumor growth in vivo. 
DISCUSSION
Unlike other mesenchymal malignancies, such as osteosarcoma and Ewing's sarcoma, which cause dramatic increases in long-term survival with the advent of systemic chemotherapy, chondrosarcoma continues to have a poor prognosis because of the absence of an effective adjuvant therapy. Chondrosarcoma shows a predilection for metastasis to the lungs. Furthermore, angiogenesis is essential for the cancer metastasis. Therefore, it is important to explore the potential target for preventing chondrosarcoma angiogenesis and metastasis. Using IHC analysis, we found that the expression of ET-1 and VEGF in chondrosarcoma patients correlated with tumor stage and higher-than-normal cartilages.
Chondrosarcoma CM-mediated tube formation and angiogenesis was abolished by ET-1 shRNA. In addition, ET-1 knockdown reduced angiogenesis and tumor growth in vivo. Our study suggests that ET-1 increased VEGF expression and subsequently promoted angiogenesis in human chondrosarcoma cells. One of the mechanisms underlying ET-1 increased VEGF production and angiogenesis through the activation of ET A R, ILK, Akt and HIF1apathways. In this study, we provided the data from clinical patients, cell experiment and animal model. Our results suggest that ET-1 promotes VEGF-dependent angiogenesis in human chondrosarcoma cells. Therefore, ET-1 may be a novel target for chondrosarcoma angiogenesis and metastasis. 
ET-1 axis represents one of the key regulators of tumorigenesis and tumor progression in several tumor cells. 23 Previous studies have shown that ET-1's contribution to VEGF production through ET A R or ET B R has a critical role in the progression of tumor malignancy. 24, 25 While, in particular, ET-1 acting through the ET A R has been implicated in progression of tumor angiogenesis. 7, 26 It has also been demonstrated that ET B R blockade by the antagonist BQ788 inhibited tumor growth and death of melanoma cells in vivo and in vitro. 27 We previously reported that ET-1 increased cell migration and matrix metalloproteinase-13 expression in human chondrosarcoma through ET A R and ET B R receptor. 13 In contrast, this study shows that ET A R-specific inhibitor BQ123 but not ET B R-specific inhibitor BQ788 abolished ET-1-induced VEGF expression and angiogenesis. These results indicate that ET-1 mediates angiogenesis and migration in human chondrosarcoma cells through a different ETR receptor.
ILK activation has been reported to regulate VEGF gene expression. 28 Recent studies have also indicated that growth factors and chemokines increased ILK activation. In this study, we examined whether ILK activation is involved in ET-1-mediated VEGF production. Stimulation of chondrosarcoma with ET-1 increased the activity of ILK, and ET-1-mediated VEGF expression and tube formation in EPCs were both inhibited by the specific ILK inhibitor KP-392. These data suggest that ILK activation is an Figure 5 . HIF-1atransactivation is involved in ET-1-induced VEGF expression and angiogenesis. (a and b) JJ012 cells were pre-treated with the HIF-1ainhibitor (10 mM) for 30 min, followed by stimulation with ET-1 (100 nM) for 24 h, and VEGF expression was examined by qPCR and ELISA. (c and d) JJ012 cells were pre-treated with the HIF-1ainhibitor (10 mM) for 30 min, followed by stimulation with ET-1 (100 nM) for 24 h. The medium was collected as CM and then applied to EPCs for 24 h. The cell migration and capillary-like structure formation in EPCs was examined by Transwell and tube formation assay. (e) JJ012 cells were incubated with ET-1 (100 ng/ml) for the indicated times and HIF-1aaccumulation in the nucleus was determined by western blotting. (f ) JJ012 cells were incubated with ET-1 (30-300 ng/ml) for 24 h, and HIF-1a mRNA expression was examined by qPCR. Results are expressed as mean ± s.e. *Po0.05 compared with control; # Po0.05 compared with ET-1-treated group.
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important signaling molecule in ET-1-induced VEGF expression and angiogenesis. Akt is the most common downstream molecule in ILK-regulated cellular function pathway. 29 Here we found that ET-1 increased the phosphorylation of Akt. Akt inhibitor and mutant also reduced ET-1-mediated VEGF expression and angiogenesis. These results suggested that ILK-dependent Akt activation is mediated by ET-1-enhanced VEGF expression and angiogenesis. In addition to gene expression, a similar signal pathway has also been reported in the ET-1-induced cell migration of ovarian carcinoma, which involved ILK-dependent Akt activation. 30 ILK-dependent Akt pathway was also involved in ET-1-inhibited prolyl hydroxylase domain 2 expression, 10 and in cancer metastasis response to ET-1, which activated the ILK/Akt pathway. 31 Taken together, our results provided evidence that ET-1 promotes VEGF expression and angiogenesis via ILK-dependent Akt activation.
Tumor metastasis is the spread of tumor cells from a primary tumor to colonize other sites of the body. Invasion, intravasation and extravasation from the circulatory system, colonization and finally angiogenesis at a distant site are the most common Figure 6 . ET A R/ILK/Akt pathway is involved in ET-1-mediated HIF-1a activation. (a) JJ012 cells were pre-treated with the BQ123, BQ788, KP392 and Akt inhibitor for 30 min, followed by stimulation with ET-1 (100 nM) for 24 h, and HIF-1a mRNA expression was examined by qPCR. (b) JJ012 cells were pre-treated with KP392 and Akt inhibitor for 30 min, followed by stimulation with ET-1 for 2 h, and then chromatin immunoprecipitation assay was then performed. Chromatin was immunoprecipitated with anti-HIF-1a. The percentage of precipitated chromatin was assayed to verify equal loading (input). (c-e) JJ012 cells were incubated with ET-1 (10-100 ng/ml) for 24 h or pre-treated with BQ123, BQ788, KP392 and Akt inhibitor for 30 min or co-transfected with ILK siRNA and Akt mutant for 24 h before exposure to ET-1. The HREdriven luciferase activity was measured, and the results were normalized to the b-galactosidase activity and expressed as mean±s.e. for three independent experiments performed in triplicate. Results are expressed as mean±s.e. *Po0.05 compared with control; # Po0.05 compared with ET-1-treated group.
Endothelin-1 enhances angiogenesis in chondrosarcoma M-H Wu et al features of tumor metastasis. Because of the prognosis of patients with chondrosarcoma, distant metastasis is generally considered as very poor. Thus, development of an antiangiogenic and antimetastatic therapy could conceivably be useful in these patients. Here we found that ET-1 induced VEGF expression and subsequently promoted angiogenesis and tumor growth in human chondrosarcoma cells through the activation of ET A R, ILK, Akt and HIF-1a signaling pathways. These findings may provide a better understanding of the mechanisms of metastasis and may lead to the development of effective therapies of chondrosarcoma.
MATERIALS AND METHODS Materials
Rabbit polyclonal antibodies specific for mammalian target of glycogen synthase kinase 3b (GSK3b) and phospho-GSK3b were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-mouse and anti-rabbit IgGconjugated horseradish peroxidase, rabbit polyclonal antibodies specific for ILK, p-Akt, Akt, b-actin, CD31, ILK siRNA, control siRNA, control-shRNA plasmid and ET-1 shRNA plasmid were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ET-1, HIF-1a and VEGF antibodies were purchased from Abcam (Cambridge, MA, USA). Recombinant human VEGF was purchased from R&D Systems (Minneapolis, MN, USA). Akt Endothelin-1 enhances angiogenesis in chondrosarcoma M-H Wu et al inhibitor was purchased from Calbiochem (San Diego, CA, USA). KP-392 was purchased from Kinetek Pharmaceuticals (Vancouver, BC, Canada). Dulbecco's modified Eagle's medium, a-minimum essential medium (MEM), fetal bovine serum and all the other cell culture reagents were purchased from Gibco-BRL Life technologies (Grand Island, NY, USA). Akt (Akt K179A) mutant and pHRE-luciferase construct were provided by Dr WM Fu (National Taiwan University, Taipei City, Taiwan). pSV-b-galactosidase vector and luciferase assay kit were purchased from Promega (Madison, WI, USA). All other chemicals were purchased from SigmaAldrich (St Louis, MO, USA). The migration assay, ELISA assay, transfection of siRNAs and hemoglobin assay are provided in Supplementary Data.
Cell culture
The human chondrosarcoma cell line (JJ012) was kindly provided by the laboratory of Dr Sean P Scully (University of Miami School of Medicine, Miami, FL, USA). The cells were cultured in complete medium containing Dulbecco's modified Eagle's medium /a-MEM supplemented with 10% fetal bovine serum. All experiments with cells were carried out at the permissive temperature (37 1C) and maintained in a humidified atmosphere of 5% CO 2 .
Isolation and cultivation of circulating EPCs
The study protocol was approved by the Institutional Review Board of Mackay Medical College (New Taipei City, Taiwan) (reference number: P1000002), and all subjects gave informed written consent before enrollment in this study. After collecting peripheral blood (80 ml) from healthy donors, the peripheral blood mononuclear cells were fractionated from other blood components by centrifugation on Ficoll-Paque plus (Amersham Biosciences, Uppala, Sweden) according to the manufacturer's instructions. CD34-positive progenitor cells were obtained from the isolated peripheral blood mononuclear cells using CD34 MicroBead kit and MACS Cell Separation System (Miltenyi Biotec, Bergisch Gladbach, Germany). The maintenance and characterization of CD34-positive EPCs were performed as described previously. 32 Briefly, human CD34-positive EPCs were maintained and propagated in MV2 complete medium, consisting of MV2 basal medium and growth supplement (PromoCell, Heidelberg, Germany), and supplied with 20% defined fetal bovine serum (HyClone, Logan, UT, USA). The cultures were seeded onto 1% gelatincoated plasticware and maintained at 37 1C in a humidified atmosphere of 5% CO 2.
Immunohistochemistry
The human chondrosarcoma tissue array was purchased from Biomax (Rockville, MD, USA; 11 cases for normal cartilage, 4 cases for type Ib chondrosarcoma and 9 cases for type IIb chondrosarcoma). The tissues were placed on glass slides, rehydrated and incubated in 3% hydrogen peroxide to block the endogenous peroxidase activity. After trypsinization, sections were blocked by incubation in 3% bovine serum albumin in phosphate-buffered saline (PBS). The primary antibody monoclonal mouse anti-human ET-1 or VEGF were applied to the slides at a dilution of 1:50 and incubated at 4 1C overnight. After being washed three times in PBS, the samples were treated with goat anti-mouse IgG biotin-labeled secondary antibodies at a dilution of 1:50. Bound antibodies were detected with an ABC kit (Vector Laboratories, Burlingame, CA, USA). The slides were stained with chromogen diaminobenzidine, washed, counterstained with Delafield's hematoxylin, dehydrated, treated with xylene and mounted. The sum of the intensity and percentage score was used as the final staining scores (0-5).
Quantitative real-time PCR Total RNA was extracted from cancer cells using a TRIzol kit (MDBio Inc., Taipei, Taiwan). The reverse transcription reaction was performed using 2 mg of total RNA that was reverse transcribed into cDNA using oligo (dT) primer. 33, 34 The quantitative real-time polymerase chain reaction (qPCR) analysis was carried out using Taqman one-step PCR Master Mix (Applied Biosystems, Foster City, CA, USA). A volume of 100 ng total cDNA was added per 25-ml reaction with sequence-specific primers and Taqman probes. Sequences for all target gene primers and probes were purchased commercially (b-actin was used as internal control) (Applied Biosystems, Foster City, CA, USA). qPCR assays were carried out in triplicate on a StepOnePlus Sequence Detection System. The cycling conditions were 10 min polymerase activation at 95 1C, followed by 40 cycles at 95 1C for Endothelin-1 enhances angiogenesis in chondrosarcoma M-H Wu et al 15 s and 60 1C for 60 s. The threshold was set above the non-template control background and within the linear phase of target gene amplification to calculate the cycle number at which the transcript was detected (denoted as C T ).
Western blot analysis
The cellular lysates were prepared as described previously. 35, 36 Proteins were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to Immobilon polyvinyldifluoride membranes. The blots were blocked with 4% bovine serum albumin for 1 h at room temperature and then probed with rabbit anti-human antibodies against ILK, GSK3b, and p-GSK3b, Akt, p-Akt, HIF-1a, PCNA or VEGF (1:1000) for 1 h at room temperature. After three washes, the blots were subsequently incubated with a donkey anti-rabbit peroxidase-conjugated secondary antibody (1:1000) for 1 h at room temperature. The blots were visualized by enhanced chemiluminescence using Kodak X-OMAT LS film (Eastman Kodak, Rochester, NY, USA).
ILK kinase assay ILK enzymatic activity was assayed in cells lysed in Nonidet P-40 buffer (0.5% sodiumdeoxycholate, 1% Nonidet P-40, 50 mM HEPES (pH 7.4), 150 mM NaCl) as reported previously. 37 Briefly, ILK was immunoprecipitated with ILK antibody overnight at 4 1C from 250 mg of lysate. After immunoprecipitation, beads were resuspended in 30 ml of kinase buffer containing 1 mg of recombinant substrate (GSK3b fusion protein) and 200 mM cold ATP, and the reaction was carried out for 30 min at 30 1C. The phosphorylated substrate was visualized by western blot with phosphoGSK3b antibody. Total GSK3b was detected with the appropriate antibody.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation analysis was performed as described previously. 38 DNA immunoprecipitated by anti-HIF-1a antibody was purified. The DNA was then extracted with phenol-chloroform. The purified DNA pellet was subjected to PCR. PCR products were then resolved by 1.5% agarose gel electrophoresis and visualized by UV light. The primers 5 0 -CCTTTGGGTTTTGCCAGA-3 0 and 5 0 -CCAAGTTTGTG-GAGCTGA-3 0 were utilized to amplify across the VEGF promoter region. 39 Transfection and reporter assay
Human chondrosarcoma cells were transfected with reporter plasmid using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. At 24 h after transfection, the cells were pre-treated with inhibitors for 30 min, and then ET-1 or vehicle was added for 24 h. Cell extracts were then prepared, and luciferase and bgalactosidase activities were measured. 13 Preparation of CM The human chondrosarcoma cell line (JJ012 cells) was grown to confluence. On reaching confluence, culture media were changed with Dulbecco's modified Eagle's medium/a-MEM without fetal bovine serum. CM was collected 2 days after the change of medium and stored at À 70 1C until use. In the series of experiments, JJ012 cells were pre-treated for 30 min with inhibitors, including BQ123, BQ788, KP392, Akt inhibitor, HIF-1a inhibitor or vehicle control (0.1% dimethylsulfoxide), and followed by treatment with ET-1 for 24 h to prevent signaling via the ET-1.
Tube formation assay
Matrigel (BD Biosciences, Bedford, MA, USA) was dissolved at 4 1C overnight and 48-well plates were prepared with 150 ml Matrigel in each well after coating and incubating at 37 1C for 30 min. EPCs (5 Â 10 4 ) were cultured in 100 ml cultured media, which also included 50% EGM-MV2 media and 50% CM. After 16 h of incubation at 37 1C, EPC tube formation was assessed with a photomicroscope, and each well was photographed at Â 200 magnification under a light microscope. Tube branches and total tube lengths were calculated using MacBiophotonics Image J software (Bethesda, MD, USA).
CAM assay
Angiogenic activity was determined using a CAM assay as described previously. 40 Fertilized chicken eggs were incubated at 38 1C in an 80% humidified atmosphere. On day 8, CM from JJ012/control-shRNA or JJ012/ ET-1-shRNA cells (2 Â 10 4 cells) were deposited in the center of the chorioallantoic. CAM results were analyzed on the fourth day. Chorioallantoid membranes were collected for microscopy and photographic documentation. Angiogenesis was quantified by counting the number of blood vessel branch; at least 10 viable embryos were tested for each treatment. All animal works were carried out in accordance with a protocol approved by the China Medical University (Taichung, Taiwan) institutional animal care and use committees.
In vivo tumor xenograft study Four-week-old male nude mice were used and randomized into two groups. For experimental cells growing exponentially, each implanted into 10 nude mice by subcutaneous injection, 1 Â 10 6 cells (JJ012/controlshRNA or JJ012/ET-1-shRNA) were resuspended in 0.1 ml of serum-free DMEM/a-MEM and injected into the right flank. After 4 weeks, the mice were killed by overdose with anesthetic. The tumor were removed and fixed in 10% formalin. The tumor volume, weight and hemoglobin concentration of tumor was measured.
Matrigel plug assay
Matrigel plug angiogenesis assay was adapted from previously described assay. 41 Thirty 4-week male nude mice were randomized into three groups: PBS (control), JJ012/control-shRNA or JJ012/ET-1-shRNA resuspended with Matrigel. Mice were subcutaneously injected with 0.4 ml Matrigel containing 2 Â 10 5 cells. On day 7, Matrigel pellets were harvested, were fixed partly with 4% formalin, embedded in paraffin and subsequently processed for IHC staining for CD31. They were also partly estimated by the Drabkin's method with Drabkin's reagent kit (Sigma) to quantify blood vessel formation.
Statistics
Data are presented as mean ± s.e.m.. Statistical comparison of two groups was performed using the Student's t-test. Statistical comparisons of more than two groups were performed using one-way analysis of variance with Bonferroni's post hoc test. In all cases, Po0.05 was considered significant.
